PP2A Inhibits Cervical Cancer Cell Migration by Dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK Signaling Pathway

Abstract

Protein phosphatase 2A (PP2A) was reported to play an important role in cancer development; however, the relationship between PP2A and cervical cancer development has yet to be fully understood. The present study aimed to explore the role of PP2A in the development of cervical cancer. Serum levels of PP2A were detected by ELISA in 23 patients with cervical cancer and 30 patients with benign cervical lesions. Furthermore, the PP2A activities and the mRNA and protein levels of PP2A were measured in cervical cancer (n=8) and chronic cervicitis (n=10) tissues. The results showed that the serum levels of PP2A were significantly reduced in patients with cervical cancer. Further studies showed that not only the activities of PP2A but also the mRNA and protein levels of PP2A were significantly decreased in cervical cancer tissues. Wound healing and Transwell assays demonstrated that pharmacological and genetic upregulation of PP2A could inhibit the migration of HeLa cells, but the downregulation of PP2A promoted cellular migration. The activation of PP2A also inhibited the remodeling of actin and the activity of mitogen-activated protein kinases (MAPKs) including p-JNK, p-p38 and p-ERK. Meanwhile, the activation of PP2A was found to downregulate MMP-9 levels, which further inhibited the migration and invasion of HeLa cells. In conclusion, our data suggest that the activity and expression of PP2A are significantly reduced in cervical cancer tissues, and the activation of PP2A may inhibit the migration of cervical cancer cells by inhibiting the phosphorylation of p-JNK, p-p38 and the p-ERK/MAPK signaling pathway as well as by downregulating MMP-9, implying that PP2A plays an important role in cervical cancer development.

Keywords

protein phosphatase 2A / HeLa cells / migration / mitogen-activated protein kinases

References

[1] HarperDM, DemarsLR. Primary strategies for HPV infection and cervical cancer prevention. Clin Obstet Gynecol, 2014, 57(2): 256-278

[2] RoqueDR, WyshamWZ, SoperJT. The surgical management of cervical cancer: an overview and literature review. Obstet Gynecol Surv, 2014, 69(7): 426-441

[3] DizonDS, MackayHJ, ThomasGM, et al.. State of the science in cervical cancer: where we are today and where we need to go. Cancer, 2014, 120(15): 2282-2288

[4] WangZ, ColePA. Catalytic mechanisms and regulation of protein kinases. Methods Enzymol, 2014, 548: 1-21

[5] SchonthalAH. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett, 2001, 170(1): 1-13

[6] ZhuLQ, ZhengHY, PengCX, et al.. Protein phosphatase 2A facilitates axonogenesis by dephosphorylating CRMP2. J Neurosci, 2010, 30(10): 3839-3848

[7] ChoUS, XuW. Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature, 2007, 445(7123): 53-57

[8] ZhangZ, MuiMZ, ChanF, et al.. Genetic analysis of B55alpha/Cdc55 protein phosphatase 2A subunits: association with the adenovirus E4orf4 protein. J Virol, 2011, 85(1): 286-295

[9] EichhornPJ, CreyghtonMP, BernardsR. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta, 2009, 1795(1): 1-15

[10] CristobalI, RinconR, MansoR, et al.. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochim Biophys Acta, 2014, 1842(9): 1823-1829

[11] DongL, ZhuJ, WenX, et al.. Involvement of SET in the Wnt signaling pathway and the development of human colorectal cancer. Oncol Lett, 2014, 7(4): 1203-1208

[12] JanghorbanM, FarrellAS, Allen-PetersenBL, et al.. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci USA, 2014, 111(25): 9157-9162

[13] WeiL, QuW, SunJ, et al.. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin. Cancer Gene Ther, 2014, 21(5): 194-199

[14] BaiXL, ZhangQ, YeLY, et al.. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther, 2014, 13(8): 2062-2072

[15] RuvoloPP, RuvoloVR, JacamoR, et al.. The protein phosphatase 2A regulatory subunit B55alpha is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta, 2014, 1843(9): 1969-1977

[16] LiuXP, ZhengHY, QuM, et al.. Upregulation of astrocytes protein phosphatase-2A stimulates astrocytes migration via inhibiting p38 MAPK in tg2576 mice. Glia, 2012, 60(9): 1279-1288

[17] TongYQ, LiuB, ZhengHY, et al.. BMI-1 autoantibody as a new potential biomarker for cervical carcinoma. PloS one, 2011, 6(11): e27804

[18] BasuS. PP2A in the regulation of cell motility and invasion. Curr Protein Pept Sci, 2011, 12(1): 3-11

[19] PloS one, 2014, 9(7):

[20] MeeusenB, JanssensV. Tumor suppressive protein phosphatases in human cancer: Emerging targets for therapeutic intervention and tumor stratification. Int J Biochem Cell Biol, 2017, S1357-2725(17): 30260-1

[21] HasanAM, Mourtada-MaarabouniM, HameedMS, et al.. Phosphoinositide 3-kinase gamma mediates chemotactic responses of human eosinophils to platelet-activating factor. Int Immunopharmacol, 2010, 10(9): 1017-1021

[22] BeraA, DasF, Ghosh-ChoudhuryN, et al.. microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKbeta-mTORCl axis to regulate renal cancer cell invasion. Exp Cell Res, 2014, 328(1): 99-127

[23] PaveseJM, OgdenIM, VollEA, et al.. Mitogen-activated protein kinase kinase4 (MAP2K4) promotes human prostate cancer metastasis. PLloS One, 2014, 9(7): el02289

[24] SizemoreGM, SizemoreST, SeachristDD, et al.. GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular regulated kinase 1/2 (ERK1/2). J Biol Chem, 2014, 289(35): 24102-24113

[25] PtakA, HoffmannM, GrucaI, et al.. Bisphenol A induce ovarian cancer cell migration via the MAPK and PI3K/Akt signalling pathways. Toxicol Lett, 2014, 229(2): 357-365

[26] YangZS, TangXJ, GuoXR, et al.. Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene (PTEN): an imaging demonstration. Onco Targets Ther, 2014, 7: 441-446

[27] GomesEG, ConnellySF, SummyJM. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo. Pancreas, 2013, 42(5): 795-806

[28] BoivinB, ChaudharyF, DickinsonBC, et al.. Receptor protein-tyrosine phosphatase alpha regulates focal adhesion kinase phosphorylation and ErbB2 oncoprotein-mediated mammary epithelial cell motility. J Biol Chem, 2013, 288(52): 36926-36935

[29] WuMY, XieX, XuZK, et al.. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/beta-catenin pathway by phosphorylation and degradation of beta-catenin. Oncol Rep, 2014, 32(2): 513-522

[30] DungTD, FengCC, KuoWW, et al.. Suppression of plasminogen activators and the MMP-2/-9 pathway by a Zanthoxylum avicennae extract to inhibit the HA22T human hepatocellular carcinoma cell migration and invasion effects in vitro and in vivo via phosphatase 2A activation. Biosci Biotechnol Biochem, 2013, 77(9): 1814-1821

[31] LiG, JiXD, GaoH, et al.. EphB3 suppresses nonsmall-cell lung cancer metastasis via a PP2A/ RACKl/Akt signalling complex. Nat Commun, 2012, 3: 667

[32] GilanO, DieschJ, AmaliaM, et al.. PR55alpha-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. Oncogene, 2014, 34(10): 1333-1339

[33] ParkMK, ParkY, ShimJ, et al.. Novel involvement of leukotriene B(4) receptor 2 through ERK activation by PP2A down-regulation in leukotriene B(4)-induced keratin phosphorylation and reorganization of pancreatic cancer cells. Biochim Biophys Acta, 2012, 1823(12): 2120-2129

[34] SwitzerCH, ChengRY, VitekTM, et al.. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene, 2011, 30(22): 2504-2513

[35] KongM, BuiTV, DitsworthD, et al.. The PP2A-associated protein alpha4 plays a critical role in the regulation of cell spreading and migration. J Biol Chem, 2007, 282(40): 29 712-29 720

[36] ChangYW, ChenMW, ChiuCF, et al.. Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-kappaB signaling in cervical cancer. Ann Surg Oncol, 2014, 21: S687-695

[37] SuiX, KongN, YeL, et al.. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett, 2014, 344(2): 174-179

[38] KimEK, ChoiEJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta, 2010, 1802(4): 396-405

[39] UekitaT, FujiiS, MiyazawaY, et al.. Oncogenic Ras/ERK signaling activates CDCP1 to promote tumorinvasion and metastasis. MCR, 2014, 12(10): 1449-1459

[40] HongB, LiH, ZhangM, et al.. p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer, 2014, 136(1): 34-43

[41] LeeT, KimSJ, SumpioBE. Role of PP2A in the regulation of p38 MAPK activation in bovine aortic endothelial cells exposed to cyclic strain. J Cell Physiol, 2003, 194(3): 349-355

[42] MengG, WangW, ChaiK, et al.. Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways. Int J Oncol, 2015, 46(3): 1007-1017

[43] GuXD, XuLL, ZhaoH, et al.. Cantharidin suppressed breast cancer MDA-MB-231 cell growth and migration by inhibiting MAPK signaling pathway. Braz J Med Biol Res, 2017, 50(7): e5920